Structure

InChI Key SVUJNSGGPUCLQZ-FQQAACOVSA-N
Smile CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.O=C(O)/C=C/C(=O)O
InChI
InChI=1S/2C21H29N6O5P.C4H4O4/c2*1-14(2)31-21(28)16(4)26-33(29,32-17-8-6-5-7-9-17)13-30-15(3)10-27-12-25-18-19(22)23-11-24-20(18)27;5-3(6)1-2-4(7)8/h2*5-9,11-12,14-16H,10,13H2,1-4H3,(H,26,29)(H2,22,23,24);1-2H,(H,5,6)(H,7,8)/b;;2-1+/t2*15-,16+,33+;/m11./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C46H62N12O14P2
Molecular Weight 1069.02
AlogP 2.97
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 11.0
Polar Surface Area 143.48
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 33.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Human immunodeficiency virus type 1 reverse transcriptase inhibitor DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
HIV Infections 4 D015658 FDA
Hepatitis B, Chronic 4 D019694 ClinicalTrials

Related Entries

MCS

Scaffolds

Mixture
Mixture
Mixture
Mixture
Mixture

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Injury, poisoning and procedural complications
14.86
General disorders and administration site conditions
10.83
Gastrointestinal disorders
9.15
Nervous system disorders
6.3
Investigations
6.05
Hepatobiliary disorders
5.04
Musculoskeletal and connective tissue disorders
4.95
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.7
Skin and subcutaneous tissue disorders
3.95
Respiratory, thoracic and mediastinal disorders
3.78
Vascular disorders
3.69
Immune system disorders
3.53
Renal and urinary disorders
3.44
Infections and infestations
2.94
Metabolism and nutrition disorders
2.85
Cardiac disorders
2.77
Surgical and medical procedures
2.35
Blood and lymphatic system disorders
2.02
Pregnancy, puerperium and perinatal conditions
2.02

Cross References

Resources Reference
ChEBI 90923
ChEMBL CHEMBL2364637
FDA SRS FWF6Q91TZO
PubChem 71511838